Approximately 85–95% of PC patients are diagnosed with either locally advanced or metastatic disease [43-45] and a previous study from our lab demonstrated that MUC16 expression is much stronger in metastatic lesions compared to the primary pancreatic tumor [33]. Here, MUC16 is linked to metastatic neoplasm.